HCB101 + bevacizumab

HCB101 + bevacizumab is a combination of two investigational and/or approved anti-cancer agents used in clinical trials to treat advanced solid tumors. **HCB101** is an investigational Fc-fusion protein targeting the SIRPα-CD47 pathway, designed to block the "do not eat me" signal and promote macrophage-mediated phagocytosis of tumor cells. **Bevacizumab** is an approved monoclonal antibody against vascular endothelial growth factor A (VEGF-A), acting as an angiogenesis inhibitor by preventing tumor blood vessel formation. The combination is being explored for synergistic anti-tumor effects, engaging immune-mediated cytotoxicity and inhibiting tumor angiogenesis. The combination is primarily under evaluation for advanced and metastatic solid tumors in ongoing early-phase clinical trials[2][4].